Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Type
Public
HQ
Milton, GB
Founded
2001
Size (employees)
482 (est)+12%
Oxford Immunotec was founded in 2001 and is headquartered in Milton, GB
Report incorrect company information

Key People/Management at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

CEO
Richard M. Altieri

Richard M. Altieri

CFO
Show more

Oxford Immunotec Office Locations

Oxford Immunotec has offices in Milton, Kohoku Ward, Marlborough and Shanghai
Milton, GB (HQ)
115D Innovation Drive Milton Park Abingdon Oxfordshire
Shanghai, CN
1701, Tower 2, Shanghai Arch Hongqiao, 533 Loushanguang Road
Kohoku Ward, JP
8F Nisso Bldg. No16, 3-8-8 Shinyokohama
Marlborough, US
200 700 Nickerson Rd
Show all (4)
Report incorrect company information

Oxford Immunotec Financials and Metrics

Oxford Immunotec Revenue

Embed Graph
Oxford Immunotec's revenue was reported to be £77.65 m in FY, 2017
GBP

Revenue (FY, 2017)

77.6 m

Gross profit (FY, 2017)

42.4 m

Gross profit margin (FY, 2017), %

54.6%

Net income (FY, 2017)

(25.8 m)

EBITDA (FY, 2017)

(38.4 m)

EBIT (FY, 2017)

(40.8 m)

Market capitalization (18-Jul-2018)

327.9 m

Closing share price (18-Jul-2018)

12.7

Cash (31-Dec-2017)

68 m
Oxford Immunotec's current market capitalization is $327.9 m.
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

12.1 m25.5 m36.6 m48.6 m64.8 m77.6 m

Revenue growth, %

44%27%

Cost of goods sold

7.3 m12.2 m17.8 m22.9 m29.6 m35.2 m

Gross profit

4.8 m13.3 m18.9 m25.7 m35.2 m42.4 m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

7.8 m50.6 m37.4 m64.9 m44.5 m68 m

Accounts Receivable

3.2 m3.1 m5 m5.5 m10 m12.8 m

Inventories

1.8 m3.6 m4.8 m5.5 m5.7 m7.7 m

Current Assets

13.5 m58.8 m49.2 m78.7 m62 m90.8 m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.7 m)(5.7 m)(16.4 m)(19 m)(16.7 m)(25.8 m)

Cash From Operating Activities

(3.7 m)(15.4 m)(12.8 m)(16.5 m)(2.9 m)

Cash From Financing Activities

46.5 m(111.7 k)41.6 m21.9 m29.8 m

Net Change in Cash

41.6 m(19.2 m)26.3 m(17.2 m)23.2 m
GBPY, 2017

Revenue/Employee

173.2 k

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Oxford Immunotec Online and Social Media Presence

Embed Graph
Report incorrect company information

Oxford Immunotec Company Life and Culture

Report incorrect company information